The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics
The paper gives data on the efficacy and safety of tumor necrosis factor-α(TNF-α) inhibitors used in first- and second-line therapy. It describes options to optimize treatment with TNF-αinhibitors in first-line therapy, by increasing the dose, which is accompanied by the greater effect only with inf...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-12-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/858 |
| id |
doaj-d317af2dc9144cca9fe98dfe6fb8c5ae |
|---|---|
| record_format |
Article |
| spelling |
doaj-d317af2dc9144cca9fe98dfe6fb8c5ae2021-07-29T09:00:12ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2018-12-01124233110.14412/1996-7012-2018-4-23-312122The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tacticsE. V. Igolkina0N. V. Chichasova1V.A. Nasonova Research Institute of Rheumatology.V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia.The paper gives data on the efficacy and safety of tumor necrosis factor-α(TNF-α) inhibitors used in first- and second-line therapy. It describes options to optimize treatment with TNF-αinhibitors in first-line therapy, by increasing the dose, which is accompanied by the greater effect only with infliximab; by changing the dose of concomitant disease-modifying antirheumatic drugs, primarily methotrexate (MTX), the use of which increases the probability of achieving the effect of TNF-αinhibitors, the magnitude of the effect rises with the larger doses of MTX or with its parenteral formulation. There are data on the effectiveness of switching from the first TNF-αinhibitor to the second TNF-αinhibitor or to a biologic agent with another mechanism of action.https://mrj.ima-press.net/mrj/article/view/858biologic agentstumor necrosis factor-αinhibitorssurvival of therapypatient registriesmethotrexate |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
E. V. Igolkina N. V. Chichasova |
| spellingShingle |
E. V. Igolkina N. V. Chichasova The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics Современная ревматология biologic agents tumor necrosis factor-αinhibitors survival of therapy patient registries methotrexate |
| author_facet |
E. V. Igolkina N. V. Chichasova |
| author_sort |
E. V. Igolkina |
| title |
The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics |
| title_short |
The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics |
| title_full |
The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics |
| title_fullStr |
The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics |
| title_full_unstemmed |
The survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics |
| title_sort |
survival rate of therapy with tumor necrosis factor-αinhibitors: main causes and drug substitution tactics |
| publisher |
IMA-PRESS LLC |
| series |
Современная ревматология |
| issn |
1996-7012 2310-158X |
| publishDate |
2018-12-01 |
| description |
The paper gives data on the efficacy and safety of tumor necrosis factor-α(TNF-α) inhibitors used in first- and second-line therapy. It describes options to optimize treatment with TNF-αinhibitors in first-line therapy, by increasing the dose, which is accompanied by the greater effect only with infliximab; by changing the dose of concomitant disease-modifying antirheumatic drugs, primarily methotrexate (MTX), the use of which increases the probability of achieving the effect of TNF-αinhibitors, the magnitude of the effect rises with the larger doses of MTX or with its parenteral formulation. There are data on the effectiveness of switching from the first TNF-αinhibitor to the second TNF-αinhibitor or to a biologic agent with another mechanism of action. |
| topic |
biologic agents tumor necrosis factor-αinhibitors survival of therapy patient registries methotrexate |
| url |
https://mrj.ima-press.net/mrj/article/view/858 |
| work_keys_str_mv |
AT evigolkina thesurvivalrateoftherapywithtumornecrosisfactorainhibitorsmaincausesanddrugsubstitutiontactics AT nvchichasova thesurvivalrateoftherapywithtumornecrosisfactorainhibitorsmaincausesanddrugsubstitutiontactics AT evigolkina survivalrateoftherapywithtumornecrosisfactorainhibitorsmaincausesanddrugsubstitutiontactics AT nvchichasova survivalrateoftherapywithtumornecrosisfactorainhibitorsmaincausesanddrugsubstitutiontactics |
| _version_ |
1721250207501385728 |